MJH Associates has acquired UBM Life Sciences’ healthcare media assets from Informa
January 2019 — MJH Associates‚ Inc. (MJH) has acquired major market media assets from the UBM Life Sciences Group of Informa PLC (INF.L). The transaction consideration was in excess of US$100 million.
MJH is the largest privately held, independent full-service medical media company in the US dedicated to delivering trusted healthcare news across multiple channels. Over 600 MJH associates are dedicated to providing healthcare professionals with the information and resources they need to optimize patient outcomes. MJH combines the reach and influence of its powerful portfolio of digital and print product lines, live events, educational programs and market research with the customization capabilities of a boutique firm. Clients include world-leading pharmaceutical, medical device, diagnostic and biotech companies.
The acquisition of UBM Life Sciences Group assets includes iconic multimedia platforms in the healthcare, animal care, pharma sciences and dental fields as well as three preeminent veterinarian conferences.
Informa is a leading international exhibitions, events, information services and scholarly research group with annual revenues approaching US$4 billion. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and provide opportunities to connect and learn.
Our role in the transaction
One of Oaklins’ TMT specialist teams in New York acted as the exclusive M&A advisor to MJH Associates in this transaction.
Michael J. Hennessy Jr.
President, MJH Associates, Inc.
Talk to the deal team
Roland DeSilva
Oaklins DeSilva+Phillips
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreNextalia has acquired a majority stake in Witapp
Nextalia SGR S.p.A. has acquired a majority stake in Witapp S.r.l., an Italian company specializing in software development for the digitization of healthcare infrastructure. The acquisition strengthens Nextalia’s track record in technology companies serving the public sector and supports its strategy of investing in businesses operating at the intersection of healthcare digitization and the modernization of public services.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn more